Zobrazeno 1 - 10
of 549
pro vyhledávání: '"Richard F. Ambinder"'
Autor:
Samantha L. Vogt, Garrick Laudin, Marianna Zahurak, Jenifer Vaughan, Atul Lakha, Sugeshnee Pather, Ziyaad Waja, Deshan Chetty, Tanvier Omar, Wendy Stevens, Philippa Ashmore, Kennedy Otwombe, Khuthadzo Hlongwane, Ravi Varadhan, Moosa Patel, Richard F. Ambinder, Neil A. Martinson, Rena R. Xian, Vinitha Philip
Publikováno v:
Infectious Agents and Cancer, Vol 19, Iss 1, Pp 1-13 (2024)
Abstract Background Prospective data from sub-Saharan Africa suggests that treatment outcomes for people living with HIV (PWH) with Hodgkin lymphoma (HL) are similar to those without HIV. However, real-world data from high-resource settings and retro
Externí odkaz:
https://doaj.org/article/1d2649f3576246e5b863051bf8f78f47
Autor:
Edina Komlodi-Pasztor, Marta Escarra-Senmarti, Danielle A. Bazer, Aastha Bhatnagar, Carlos A. Perez Heydrich, Marcus Messmer, Richard F. Ambinder, Douglas E. Gladstone, Laura Clayton, Amy Goodrich, Laura Schoch, Nina Wagner-Johnston, Christopher J. VandenBussche, Peng Huang, Matthias Holdhoff, Maximillian Rosario
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The monoclonal antibody rituximab improves clinical outcome in the treatment of CD20-positive lymphomatous neoplasms, and it is an established drug for treatment of these cancers. Successful mRNA COVID-19 (SARS-CoV-2) vaccination is extremely importa
Externí odkaz:
https://doaj.org/article/231eb2a41b7d476ea9cd7853570c0c4f
Autor:
Maggie Li, Barbara J. Smith, Jaeyeun Lee, Jennifer Petr, Nicole M. Anders, Robyn Wiseman, Michelle A. Rudek, Richard F. Ambinder, Prashant J. Desai
Publikováno v:
Infectious Agents and Cancer, Vol 19, Iss 1, Pp 1-13 (2024)
Abstract Background Antiviral therapies that target herpesviruses are clinically important. Nelfinavir is a protease inhibitor that targets the human immunodeficiency virus (HIV) aspartyl protease. Previous studies demonstrated that this drug could a
Externí odkaz:
https://doaj.org/article/5c85366898714cc8a83db117ba7dffca
Autor:
Laura E. Martínez, Shelly Lensing, Di Chang, Larry I. Magpantay, Ronald Mitsuyasu, Richard F. Ambinder, Joseph A. Sparano, Otoniel Martínez-Maza, Marta Epeldegui
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Emerging evidence shows that tumor cells secrete extracellular vesicles (EVs) that carry bioactive cell surface markers, such as programmed death-ligand 1 (PD-L1), which can modulate immune responses and inhibit anti-tumor responses, potenti
Externí odkaz:
https://doaj.org/article/9d5e5c4b635e42f487b6b2ffaa7bc2ea
Autor:
Samantha L. Vogt, Moosa Patel, Atul Lakha, Vinitha Philip, Tanvier Omar, Philippa Ashmore, Sugeshnee Pather, Lisa M. Haley, Gang Zheng, Jennifer Stone, Elizabeth Mayne, Wendy Stevens, Nina Wagner-Johnston, Christopher D. Gocke, Neil A. Martinson, Richard F. Ambinder, Rena R. Xian
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 611-621 (2021)
PURPOSEDiagnosis of AIDS lymphoma in low-resource settings, like South Africa, is often delayed, leaving patients with limited treatment options. In tuberculosis (TB) endemic regions, overlapping signs and symptoms often lead to diagnostic delays. As
Externí odkaz:
https://doaj.org/article/a13f57b2b79345a29f25b7e23e037256
Autor:
Rena R. Xian, Tobias Kinyera, Isaac Otim, Joshua N. Sampson, Hadijah Nabalende, Ismail D. Legason, Jennifer Stone, Martin D. Ogwang, Steven J. Reynolds, Patrick Kerchan, Kishor Bhatia, James J. Goedert, Sam M. Mbulaiteye, Richard F. Ambinder
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in regions of equatorial Africa where P. falciparum malaria is holoendemic. The tumor is consistently associated with Epstein-Barr virus (EBV). Screening for EBV DNA in plasma in a hi
Externí odkaz:
https://doaj.org/article/9dfbb1ef324146c49971c60d64c8f4d2
Autor:
Polina Shindiapina, Maciej Pietrzak, Michal Seweryn, Eric McLaughlin, Xiaoli Zhang, Mat Makowski, Elshafa Hassan Ahmed, Sarah Schlotter, Rebecca Pearson, Rhonda Kitzler, Anna Mozhenkova, Jennifer Le-Rademacher, Richard F. Little, Gorgun Akpek, Ernesto Ayala, Steven M. Devine, Lawrence D. Kaplan, Ariela Noy, Uday R. Popat, Jack W. Hsu, Lawrence E. Morris, Adam M. Mendizabal, Amrita Krishnan, William Wachsman, Nita Williams, Nidhi Sharma, Craig C. Hofmeister, Stephen J. Forman, Willis H. Navarro, Joseph C. Alvarnas, Richard F. Ambinder, Gerard Lozanski, Robert A. Baiocchi
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
We report a first in-depth comparison of immune reconstitution in patients with HIV-related lymphoma following autologous hematopoietic cell transplant (AHCT) recipients (n=37, lymphoma, BEAM conditioning), HIV(-) AHCT recipients (n=30, myeloma, melp
Externí odkaz:
https://doaj.org/article/11e102a0fff440d19a1c2e8eecf7cba8
Autor:
Philip H. Imus, Hua-Ling Tsai, Leo Luznik, Ephraim J. Fuchs, Carol Ann Huff, Douglas E. Gladstone, Patrick Lowery, Richard F. Ambinder, Ivan M. Borrello, Lode J. Swinnen, Nina Wagner-Johnston, Christian B. Gocke, Syed Abbas Ali, F.Javier Bolaños-Meade, Ravi Varadhan, Richard J. Jones
Publikováno v:
Blood Advances, Vol 3, Iss 17, Pp 2608-2616 (2019)
Abstract: Hematologic malignancies in older people are unlikely to be cured with chemotherapy alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially nonmyeloablative (NMA) conditioning and the use of haploidentical donors
Externí odkaz:
https://doaj.org/article/197de5e065234acea249f8b75efa3cfa
Autor:
Joseph A. Sparano, Jeannette Y. Lee, Lawrence D. Kaplan, Juan Carlos Ramos, Richard F. Ambinder, William Wachsman, David Aboulafia, Ariela Noy, David H. Henry, Lee Ratner, Ethel Cesarman, Amy Chadburn, Ronald Mitsuyasu
Publikováno v:
Haematologica, Vol 106, Iss 3 (2020)
Four cycles of rituximab plus CHOP chemotherapy is as effective as 6 cycles in low-risk diffuse large B-cell lymphoma (DLBCL). Here we report a post-hoc analysis of a prospective clinical trial in patients with HIV-associated DLBCL and high-grade lym
Externí odkaz:
https://doaj.org/article/078d20628e604f39b442cee01904788e
Autor:
Amy S. Duffield, Maria Libera Ascierto, Robert A. Anders, Janis M. Taube, Alan K. Meeker, Shuming Chen, Tracee L. McMiller, Neil A. Phillips, Haiying Xu, Aleksandra Ogurtsova, Alan E. Berger, Drew M. Pardoll, Suzanne L. Topalian, Richard F. Ambinder
Publikováno v:
Blood Advances, Vol 1, Iss 17, Pp 1324-1334 (2017)
Abstract: Classical Hodgkin lymphoma (CHL) is a neoplasm characterized by robust inflammatory infiltrates and heightened expression of the immunosuppressive PD-1/PD-L1 pathway. Although anti-PD-1 therapy can be effective in >60% of patients with refr
Externí odkaz:
https://doaj.org/article/a34c1ebc512840c184df62031f0ea438